pharmacie et médicaments – Décisions de la CT de la HAS - Médicaments innovants -Myélome multiple

This written question concerns decisions made by the HAS (High Authority for Health) committee regarding innovative medicines for treating multiple myeloma. It seeks clarification on the evaluation and approval process for these new treatments, potentially affecting patients and the pharmaceutical industry.